ClinicalTrials.gg
RecruitingNCT06778447RESTOREUpdated Sep 14, 2026

Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease

An interventional study of VIA Disc NP and Sham in Degenerative Disc Disease, Disc Degeneration and Lumbar Discogenic Pain, sponsored by VIVEX Biologics, Inc.. Recruiting at 19 sites in United States. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by VIVEX Biologics, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
22 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Planned enrollment
12th of 141
325 · median 57
Started
2025
with 8 others
No phase
90 of 232
15 open now
Primary completion
2027-10
later than 37 of 57 live
Registered
220th of 232
by date

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 12th largest by planned enrollment of the 141 interventional ones that give a count, is one of 9 that started in 2025, is one of 90 with no phase, reaches primary completion later than 37 of the 57 other live ones, and was the 220th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 22 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

VIA Disc NP is a non-surgical intervention intended to supplement nucleus pulposus tissue in degenerated intervertebral discs.

This is a randomized, sham-controlled, multi-center, double-blind clinical trial with an open label roll-in period of one participant per site in which participants with lumbar discogenic pain associated with DDD will receive one VIA Disc NP treatment to each affected level (up to 2 levels). Participants enrolled after the roll-in stage will be randomized on a 2:1 basis to receive either a single VIA Disc NP intradiscal injection at 1 or 2 levels or the sham procedure at 1 or 2 levels. At 12 months, participants in the sham arm with continued symptoms may cross-over, receive VIA Disc NP, and will restart the study visit schedule, completing an additional 12 months of follow-up post-cross-over.

03

Conditions studied

  • Degenerative Disc Disease
  • Disc Degeneration
  • Lumbar Discogenic Pain

Keywords

  • Degenerative Disc Disease
  • Lumbar Discogenic Pain
04

Who can participate

Ages eligible
22 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 22 to 85 years old
  • Diagnosis of moderate to severe DDD on MRI, Modified Pfirrmann Grade 3-7
  • Chronic axial midline low-back pain in the absence of lower extremity motor/sensory/reflex changes with or without referred non-radicular leg pain for at least 6 months prior to screening; unresponsive to at least 3 months of conservative care
  • Low-back pain severity score of ≥ 40 to ≤ 90 mm on the VAS
  • ODI score of ≥ 40 to ≤ 80
  • Positive sustained hip flexion test
  • Intolerance to prolonged sitting
  • Able to give voluntary, written to participate and have signed an Informed Consent Form specific to this study
  • Willing and able to comply with all study procedures and availability for the duration of the study with a of > 2 years

Exclusion criteria

Exclusion Criteria:

  • to the proposed sedation/anesthetic protocol
  • Involvement of more than two lumbar discs as evidenced by 3 or more discs with Modified Pfirrmann grade of 3 or greater
  • Symptomatic vertebral compression fracture
  • Previous surgical treatment of the lumbar spine
  • History of sacroiliac (SI) joint fusion within the past six months
  • Received lumbar epidural or intradiscal injection, lumbar facet joint steroid injection, lumbar radiofrequency ablation, SI joint pain injection, injection of methylene blue, dextrose, glucosamine, and chondroitin sulfate, or biacuplasty within 3 months of the Day 0 procedure
  • Received intraosseous radiofrequency nerve ablation procedure at the same or adjacent level (e.g., Basivertebral nerve ablation or sinuvertebral nerve ablations)
  • Received prior intradiscal stem cell/progenitor cell therapy or other biological intervention (e.g., MSC, PRP) at the target level within 12 months of the Day 0 procedure
  • Evidence of dynamic instability on lumbar flexion-extension radiographs (>3 mm) at any level
  • Grade 2 or higher spondylolisthesis at the target level, lumbar spondylitis or other undifferentiated spondyloarthropathy, or Type III Modic changes adjacent to the target disc
  • Radiographic evidence of a full thickness annular tear at the target disc or other abnormal disc morphology
  • Clinical suspicion of facet pain as primary pain generator
  • A systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study (e.g. current systemic infection, uncontrolled disease, uncontrolled immunodeficiency disease, recent history of myocardial infarction, uncontrolled diabetes (>7.0% ), etc.)
  • Received VIA Disc NP previously.
  • Deemed unsuitable for clinical study participation by the Investigator
  • Evidence of substance abuse (including marijuana); note: subjects using prescribed extended-release narcotics (e.g., fentanyl patch, MS Contin, oxycontin) within the 3 months prior to screening and subjects on long-acting opioids may be given option to wean off opiates before enrollment; participants on short-acting opiates (e.g., hydrocodone, oxycodone, tramadol, etc.) may be included and utilization monitored after the treatment
  • Opioid use of more than 90 MME/day
  • Currently receiving treatment with radiation, chemotherapy, , or chronic steroid therapy (prednisone, or its equivalent, use of up to 5 mg/qd, or inhalation steroids for asthma is allowed)
  • Metal or ceramic implants in the lumbar spine region
  • Contraindications to MRI, including non-MRI compatible devices and active implantable devices such as spinal cord stimulators, intrathecal pumps, etc.
  • Involved in ongoing or closed (within 6 months of screening visit) litigation related to their back pain condition
  • Any mental instability, unstable bipolar disorders, unmanaged post-traumatic stress disorder (PTSD) or uncontrolled anxiety/depression and/or require new or changed anti-depressants or anti-psychotic medications within 3 months of enrollment
  • Diagnosis of any traumatic neurological disorders that may impact the study as per the judgement of the Investigator
  • Women who are pregnant or breastfeeding at the time of enrollment and/or plan to become pregnant during the study; pregnancy is confirmed by:
  • a positive pregnancy test during the screening visit
  • self-reported pregnancy
  • Women of (WOCBP) who are not using a reliable form of (as determined by the Investigator)
  • Received any experimental drug or device to treat the same condition used within 6 months prior to the screening visit or during the course of the clinical trial
  • Other persistent pain/nerve issues including, for example, radiculopathy, cauda equine syndrome, etc.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
325 participants (estimated)

Study arms

  • Experimental
    VIA Disc NP

    A single dose, intradiscal delivery of 100mg of VIA Disc NP mixed with sterile saline according to product Instructions for Use (IFU) and administered at up to two affected levels, L1-S1.

    Other: VIA Disc NP

  • Sham comparator
    Sham

    The procedure will be identical to the investigational procedure with the following exception: A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc. No saline or VIA Disc NP will be injected.

    Other: Sham

Interventions

  • OtherVIA Disc NP

    VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.

    Also known as: VIA Disc Nucleus Pulposus Allograft

  • OtherSham

    A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc. No saline or VIA Disc NP will be injected.

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint - Proportion of participants achieving MCID in VAS score from baseline to 12 months.

    The primary efficacy endpoint is the proportion of participants who achieve a minimal clinically important difference (MCID), defined as at least a 30% reduction in back pain VAS score from baseline to 12 months, in the VIA Disc NP group compared to that in the sham-control group.

    Time frame: Baseline to 12 Months

  2. Primary Safety Endpoint - Proportion of participants reporting treatment-related AEs at 12 months.

    The primary safety endpoint will be the proportion of participants that experience one or more treatment-related (Investigational Product (IP) or procedure), adverse events (AE) in the VIA Disc NP group compared to the sham-control group at 12 months.

    Time frame: Baseline to 12 Months

07

Study locations

19 of 19 sites recruiting
  • Interventional Pain Management Napa Valley Orthopedic Medical Group
    Napa, California 94558, United States
    Recruiting
    • Sarah Habib · Contact
    • Jackie Weisbein, MD · Principal investigator
  • Source Healthcare
    Santa Monica, California 90403, United States
    Recruiting
    • Gabriel Wirnowski · Contact
    • Tim Davis, MD · Principal investigator
  • Premier Spine and Pain Institute
    Thornton, Colorado 80229, United States
    Recruiting
    • Dennis Dickman · Contact
    • Amar Patel, MD · Principal investigator
  • The Orthopaedic Institute
    Gainesville, Florida 32607, United States
    Recruiting
    • Aldrin Yumil · Contact
    • Ajay Antony, MD · Principal investigator
  • Georgia Pain Management
    Woodstock, Georgia 30189, United States
    Recruiting
    • Tina Hall · Contact
    • James Ellner, MD · Principal investigator
  • Henry Community Health
    New Castle, Indiana 47362, United States
    Recruiting
    • Rebecca Layman · Contact
    • Andrew Davisson, MD · Principal investigator
  • University of Kansas
    Kansas City, Kansas 66160, United States
    Recruiting
    • Karina Bravo · Contact
    • Usman Latif, MD · Principal investigator
  • University of Kentucky
    Lexington, Kentucky 40504, United States
    Recruiting
    • Katie Eastridge · Contact
    • Christopher Mallard, MD · Principal investigator
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70115, United States
    Recruiting
    • Raquel Walker · Contact
    • Maged Guirguis, MD · Principal investigator
  • Spine Institute of Louisiana
    Shreveport, Louisiana 71101, United States
    Recruiting
    • Krista Kachnik · Contact
    • Pierce Nunley, MD · Principal investigator
  • Paradigm Health System
    Slidell, Louisiana 70458, United States
    Recruiting
    • Chris Minnerly · Contact
    • Thomas Myers, MD · Principal investigator
  • Nevada Advanced Pain Specialists
    Reno, Nevada 89511, United States
    Recruiting
    • Madeline Benson · Contact
    • Denis Patterson, DO · Principal investigator
  • Premier Pain Centers
    Shrewsbury, New Jersey 07702, United States
    Recruiting
    • Kathryn Gee · Contact
    • Sean Li, MD · Principal investigator
  • Northwell Health
    New York, New York 10019, United States
    Recruiting
    • Jarka Faruq · Contact
    • Kiran Patel, MD · Principal investigator
  • Crystal Coast Pain Management
    New Bern, North Carolina 28560, United States
    Recruiting
    • Amy Harum · Contact
    • Kirk Harum, MD · Principal investigator
  • Pacific Sports & Spine
    Eugene, Oregon 97404, United States
    Recruiting
    • Katie Fabian · Contact
    • Greg Moore, MD · Principal investigator
  • Procura Pain & Spine
    Shenandoah, Texas 77384, United States
    Recruiting
    • Courtney Harvey · Contact
    • Thomas White, MD · Principal investigator
  • Precision Spine Care
    Tyler, Texas 75701, United States
    Recruiting
    • Jessica Youngblood · Contact
    • Aaron Calodney, MD · Principal investigator
  • The Spine and Nerve Center C/O Clinical Research
    Charleston, West Virginia 25301, United States
    Recruiting
08

References and documents

Publications

  • Deer TR, Nunley PD, Naidu RK, Beall DP, Davis TT, Calodney AK, Soin A, Lorio MP, Block JE. Safety and efficacy of intradiscal nucleus pulposus allograft versus sham for lumbar discogenic pain associated with degenerative disc disease: study protocol for a randomized clinical trial. Trials. 2026 Jun 8. doi: 10.1186/s13063-026-09826-w. Online ahead of print. PubMed 42260665 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Oct 2027, 32 months after the start.

Of 45 industry-sponsored interventional studies with no phase under Intervertebral Disc Degeneration, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 82. This study's planned 32 months is below that.

Counting every sponsor, half of 85 studies reached it within 50 months; a quarter within 27 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Jan 16, 2025
StartActual
Feb 17, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2028
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06778447
Lead sponsor
VIVEX Biologics, Inc.
Responsible party
Sponsor
First posted
Jan 16, 2025
Start date
Feb 17, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2028 (estimated)
Last update
Sep 14, 2026

Study contacts

Jennifer Martin
Contact
jmartin@vivex.com
303-378-9778

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion